Founder's Message
Founder Perspective
“We began with a fundamental observation: the biological processes that damage the cardiovascular
system also impair brain health. Chronic vascular inflammation, endothelial dysfunction, and impaired
blood flow affect the brain as directly as they affect the heart. That insight led us to the Mas receptor
pathway, a neurovascular mechanism that regulates inflammation, cerebral perfusion, and vascular
resilience. By targeting this pathway, we aim to address the biological drivers of cognitive decline rather
than its late-stage consequences. In a field with no approved therapies for vascular dementia,
ProNeurogen is focused on moving decisively—from mechanism to clinic—so patients can preserve
cognition, independence, and quality of life. After more than a decade of federally supported research,
we have built a development platform designed for global advancement with the right partner, grounded
in scientific rigor, regulatory discipline, and institutional transparency."
DR. MEREDITH HAY,
Founder & Chair, ProNeurogen
Founder Perspective
“We began with a fundamental observation: the biological processes that damage the cardiovascular system also impair brain health. Chronic vascular inflammation, endothelial dysfunction, and impaired blood flow affect the brain as directly as they affect the heart. That insight led us to the Mas receptor pathway, a neurovascular mechanism that regulates inflammation, cerebral perfusion, and vascular resilience. By targeting this pathway, we aim to address the biological drivers of cognitive decline rather than its late-stage consequences. In a field with no approved therapies for vascular dementia, ProNeurogen is focused on moving decisively—from mechanism to clinic—so patients can preserve cognition, independence, and quality of life. After more than a decade of federally supported research, we have built a development platform designed for global advancement with the right partner, grounded in scientific rigor, regulatory discipline, and institutional transparency."
DR. MEREDITH HAY,
Founder & Chair, ProNeurogen
Founder Perspective
“We began with a fundamental observation: the biological processes that damage the cardiovascular system also impair brain health. Chronic vascular inflammation, endothelial dysfunction, and impaired blood flow affect the brain as directly as they affect the heart. That insight led us to the Mas receptor pathway, a neurovascular mechanism that regulates inflammation, cerebral perfusion, and vascular resilience. By targeting this pathway, we aim to address the biological drivers of cognitive decline rather than its late-stage consequences. In a field with no approved therapies for vascular dementia, ProNeurogen is focused on moving decisively—from mechanism to clinic—so patients can preserve cognition, independence, and quality of life. After more than a decade of federally supported research, we have built a development platform designed for global advancement with the right partner, grounded in scientific rigor, regulatory discipline, and institutional transparency."
DR. MEREDITH HAY,
Founder & Chair, ProNeurogen
Meredith is the visionary and one of the inventors
of the founding technology. She has over 30
years of experience in neuroscience and
cardiovascular neurophysiology. She is the former
Executive Vice President and Chief Operating
Officer for the University of Arizona for former Vice
President for Research, University of Iowa. She
currently is a tenured professor at the University of
Arizona College of Medicine. Dr. Hay has generated
over $50 M in external R&D funding and nearly 30
NIH and related grants.
Meredith is the visionary and one of the inventors
of the founding technology. She has over 30
years of experience in neuroscience and
cardiovascular neurophysiology. She is the former
Executive Vice President and Chief Operating
Officer for the University of Arizona for former Vice
President for Research, University of Iowa. She
currently is a tenured professor at the University of
Arizona College of Medicine. Dr. Hay has generated
over $50 M in external R&D funding and nearly 30
NIH and related grants.
Meredith Hay, PH.D.
Meredith Hay, PH.D.
Founder and Chief Executive Officer
Tamara brings a wealth of experience in technology
commercialization, intellectual property, technology
transfer, start-ups and early stage commercialization
to this project. She has over 25 years of experience
in technology development, intellectual property,
contract negotiation and commercialization of
emerging technologies. She most recently served
as Senior Counsel for Accenture, plc, a leading
multinational technology consulting firm. She is
licensed to practice law in the states of NY, MA,
DC and AZ.
Tamara brings a wealth of experience in technology
commercialization, intellectual property, technology
transfer, start-ups and early stage commercialization
to this project. She has over 25 years of experience
in technology development, intellectual property,
contract negotiation and commercialization of
emerging technologies. She most recently served
as Senior Counsel for Accenture, plc, a leading
multinational technology consulting firm. She is
licensed to practice law in the states of NY, MA,
DC and AZ.
Tamara Crockett, ESQ
Tamara Crockett, ESQ
President, Director and IP Advisor
Peter has 30+ years' experience in leading CMC
and regulatory activities in the biomedical industry.
Peter has held various positions, including Chief
Regulatory Officer, Chief Operations Officer, Vice
President of CMC and Head of Operations for several
US-based companies. Peter started his career at
Genentech, where he held several technical and
leadership positions in pharmaceutical development
and manufacturing and drug delivery.
Peter has 30+ years' experience in leading CMC
and regulatory activities in the biomedical industry.
Peter has held various positions, including Chief
Regulatory Officer, Chief Operations Officer, Vice
President of CMC and Head of Operations for several
US-based companies. Peter started his career at
Genentech, where he held several technical and
leadership positions in pharmaceutical development
and manufacturing and drug delivery.
Peter Knauer
Peter Knauer
Director of Regulatory Affairs and Manufacturing
Chris has more than 35 years' experience in peptide
chemistry, manufacturing and therapeutics
development including Executive Director of R&D at
Amylin Pharmaceutical, and CEO and Founder of Drug
Delivery Experts, San Diego, Ca.
Chris Rhodes, PH.D.
Peptide Formulation Development
Nina brings broad experience in both the technical
and business side of the pharmaceutical industry.
Dr. Ossanna manages product development and
partner relationships and has extensive experience
in IND development and multicenter clinical trails.
Nina Ossanna, PH.D.
Director of Product Development
LEADERSHIP
LEADERSHIP
Chris has more than 35 years' experience in peptide
chemistry, manufacturing and therapeutics
development including Executive Director of R&D at
Amylin Pharmaceutical, and CEO and Founder of Drug
Delivery Experts, San Diego, Ca.
Chris has more than 35 years' experience in peptide
chemistry, manufacturing and therapeutics
development including Executive Director of R&D at
Amylin Pharmaceutical, and CEO and Founder of Drug
Delivery Experts, San Diego, Ca.
Chris Rhodes, PH.D.
Peptide Formulation Development
Nina brings broad experience in both the technical
and business side of the pharmaceutical industry.
Dr. Ossanna manages product development and
partner relationships and has extensive experience
in IND development and multicenter clinical trails.
Nina brings broad experience in both the technical
and business side of the pharmaceutical industry.
Dr. Ossanna manages product development and
partner relationships and has extensive experience
in IND development and multicenter clinical trails.
Nina Ossanna, PH.D.
Director of Product Development
BOARD OF DIRECTORS
BOARD OF DIRECTORS
Meredith Hay, PH.D.
Meredith Hay, PH.D.
ProNeurogen Founder, CEO & Board Chair
Professor of Physiology, Psychology and McKnight Brain Institute, University of Arizona
ProNeurogen Founder, CEO & Board Chair
Professor of Physiology, Psychology and McKnight Brain Institute, University of Arizona
ProNeurogen Founder, CEO & Board Chair
Professor of Physiology, Psychology and McKnight Brain Institute, University of Arizona
Dr. Hay joined ProNeurogen's board of directors in 2014. She is the original founder of the company and an inventor of the technologies. She has over 30 years of experience in neuroscience and is an expert in cardiovascular neuropharmacology.
Dr. Hay joined ProNeurogen's board of directors in 2014. She is the original founder of the company and an inventor of the technologies. She has over 30 years of experience in neuroscience and is an expert in cardiovascular neuropharmacology.
Gillian Thackray, ESQ
Gillian Thackray, ESQ
Previous Vice President & Chief IP Counsel, ThermoFisher Scientific
Previous Vice President & Chief IP Counsel, ThermoFisher Scientific
Ms. Thackray is an award-winning lawyer who protects the rights of some of the world’s most high-tech innovators. Her multi-faceted approach integrates law, business, and practicality to help clients reach their goals. She is registered to practice at the USPTO, and admitted in California.
President and ProNeurogen Director
President and ProNeurogen Director
President and ProNeurogen Director
Tamara Crockett, ESQ
Tamara Crockett, ESQ
Ms. Crockett joined the board of directors in 2014. Tamara is an attorney with 25+ years experience in technology development, intellectual property, contract negotiation and commercialization of emerging technologies. She most recently served as Senior Counsel for Accenture, plc, a leading multinational technology consulting firm. She is licensed in the states of NY, MA, DC and AZ.
Ms. Crockett joined the board of directors in 2014. Tamara is an attorney with 25+ years experience in technology development, intellectual property, contract negotiation and commercialization of emerging technologies. She most recently served as Senior Counsel for Accenture, plc, a leading multinational technology consulting firm. She is licensed in the states of NY, MA, DC and AZ.
Retired, Argonne National Laboratory, USA and ProNeurogen Director
Retired, Argonne National Laboratory, USA and ProNeurogen Director
Elizabeth Hocking, ESQ
Ms. Hocking joined the board of directors in 2015. Ms. Hocking has over 30 years of experience as a federal policy analyst and currently serves as ProNeurogen’s Board Secretary.
Ms. Thackray is an award-winning lawyer who protects the rights of some of the world’s most high-tech innovators. Her multi-faceted approach integrates law, business, and practicality to help clients reach their goals. She is registered to practice at the USPTO, and admitted in California.
Ms. Crockett joined the board of directors in 2014. Tamara is an attorney with 25+ years experience in technology development, intellectual property, contract negotiation and commercialization of emerging technologies. She most recently served as Senior Counsel for Accenture, plc, a leading multinational technology consulting firm. She is licensed in the states of NY, MA, DC and AZ.
BUSINESS ADVISORY BOARD
BUSINESS ADVISORY BOARD
Nick Hare
Nick Hare
Nick Hare
Nick Hare is the Founder & Principal of NBH Advisory and a board member with two decades of global executive experience leading high-stakes transactions and enterprise-scale transformations across industries and borders. He has sponsored ten acquisitions and integrations, creating over three billion in value and scaling platforms in over fifty countries under pressure in harsh environments. He combines a buyer’s perspective shaped by acquirer logic with an operator’s discipline forged through global operations, giving clients a rare dual vantage point.
Nick Hare is the Founder & Principal of NBH Advisory and a board member with two decades of global executive experience leading high-stakes transactions and enterprise-scale transformations across industries and borders. He has sponsored ten acquisitions and integrations, creating over three billion in value and scaling platforms in over fifty countries under pressure in harsh environments. He combines a buyer’s perspective shaped by acquirer logic with an operator’s discipline forged through global operations, giving clients a rare dual vantage point.
Peter Barton Hutt
Peter Barton Hutt
Peter Barton Hutt is a senior counsel in the Washington, DC law firm of Covington & Burling LLP, specializing in Food and Drug Law. Mr. Hutt is a member of the National Academy of Medicine is a member of the Board of Directors of the Critical Path Institute. From 1971 to 1975 Mr. Hutt was Chief Counsel for the Food and Drug Administration. During his tenure as FDA Chief Counsel, Mr. Hutt led the transformation of the agency from outdated law enforcement to modern administrative law.
Peter Barton Hutt is a senior counsel in the Washington, DC law firm of Covington & Burling LLP, specializing in Food and Drug Law. Mr. Hutt is a member of the National Academy of Medicine is a member of the Board of Directors of the Critical Path Institute. From 1971 to 1975 Mr. Hutt was Chief Counsel for the Food and Drug Administration. During his tenure as FDA Chief Counsel, Mr. Hutt led the transformation of the agency from outdated law enforcement to modern administrative law.
Jack Dean, PH.D.
Jack Dean, PH.D.
Dr. Jack Dean retired in January, 2006 as President, U.S. Science and Medical Affairs (R&D), Sanofi- Aventis, Malvern, PA and as the Global Director of Preclinical Development for Sanofi-Aventis, SA (Paris). During his tenure at Sanofi and legacy companies (18 years) he was involved with the registration of twelve NDAs for the US and global market including Plavix, Avapro, Avalide, Ambien CR, and Eloxatin as examples. He also led the reorganization of global preclinical development through three corporate mergers (Sterling-Winthrop, Synthelabo, and Aventis).
Dr. Jack Dean retired in January, 2006 as President, U.S. Science and Medical Affairs (R&D), Sanofi- Aventis, Malvern, PA and as the Global Director of Preclinical Development for Sanofi-Aventis, SA (Paris). During his tenure at Sanofi and legacy companies (18 years) he was involved with the registration of twelve NDAs for the US and global market including Plavix, Avapro, Avalide, Ambien CR, and Eloxatin as examples. He also led the reorganization of global preclinical development through three corporate mergers (Sterling-Winthrop, Synthelabo, and Aventis).
Dr. Jack Dean retired in January, 2006 as President, U.S. Science and Medical Affairs (R&D), Sanofi- Aventis, Malvern, PA and as the Global Director of Preclinical Development for Sanofi-Aventis, SA (Paris). During his tenure at Sanofi and legacy companies (18 years) he was involved with the registration of twelve NDAs for the US and global market including Plavix, Avapro, Avalide, Ambien CR, and Eloxatin as examples. He also led the reorganization of global preclinical development through three corporate mergers (Sterling-Winthrop, Synthelabo, and Aventis).
Steve Arneric, PH.D.
Steve Arneric, PH.D.
Dr. Stephen P. Arneric is a pharmaceutical scientist and leader with a proven track record in delivering differentiated therapeutics. His experience spans more than 25 years of large pharma (Abbott, Lilly, Pharmacia, & Pfizer), biotechnology (DuPont Pharmaceuticals, Neuromed Pharmaceuticals), and academic service (University of Iowa, Cornell Medical College, Southern Illinois University School of Medicine), resulting in over 30 drug candidates entering into clinical development to treat pain and psychiatric and urological disorders. His Launched Product Development experience includes the following: Exalgo™ , Esreboxetine , Dynastat™ , Lyrica™ (neuropathic pain), Cymbalta™ and Detrol™ .
Dr. Stephen P. Arneric is a pharmaceutical scientist and leader with a proven track record in delivering differentiated therapeutics. His experience spans more than 25 years of large pharma (Abbott, Lilly, Pharmacia, & Pfizer), biotechnology (DuPont Pharmaceuticals, Neuromed Pharmaceuticals), and academic service (University of Iowa, Cornell Medical College, Southern Illinois University School of Medicine), resulting in over 30 drug candidates entering into clinical development to treat pain and psychiatric and urological disorders. His Launched Product Development experience includes the following: Exalgo™ , Esreboxetine , Dynastat™ , Lyrica™ (neuropathic pain), Cymbalta™ and Detrol™ .
SCIENTIFIC ADVISORY BOARD
SCIENTIFIC ADVISORY BOARD
Carol A. Barnes, PH.D.
Carol A. Barnes, PH.D.
One of the worlds leading neuroscientists and an expert in memory biology and aging with over 30 years experience in the field. Director of the Evelyn F. McKnight Institute and a regents' professor in the Departments of Psychology and Neurology at the University of Arizona.
Costantino Iadecola, M.D.
Costantino Iadecola, M.D.
A world leader in vascular dementia with nearly 30 years experience in neurology and neuroscience. Dr. Iadecola is the Director of the Brain and Mind Research Institute Weill Cornell Medical College and Professor of Neurology and Neuroscience Weill Cornell Medical College.
Eric Reiman, M.D.
Eric Reiman, M.D.
International leader in the area of developing new therapies to prevent and treat Alzheimer’s disease. CEO of Banner Research and Executive Director of the Banner Alzheimer’s institute in Phoenix, AZ International renowned clinical Has over 25 years experience in dementia and Alzheimer’s disease.
International leader in the area of developing new therapies to prevent and treat Alzheimer’s disease. CEO of Banner Research and Executive Director of the Banner Alzheimer’s institute in Phoenix, AZ International renowned clinical Has over 25 years experience in dementia and Alzheimer’s disease.
Raymond Woosley, M.D., Ph.D.
Raymond Woosley, M.D., Ph.D.
Dr. Woosely has over 30 years experience in clinical research, developing new therapeutics, and working with the FDA. The founding President and Chairman of the Board for AZCERT and founder and past President of Critical Path Institute (C-Path).
